Clovis Oncology Inc. (CLVS)

24.00
1.63 7.29
NASDAQ : Health Technology
Prev Close 22.37
Open 22.36
Day Low/High 21.66 / 24.11
52 Wk Low/High 11.50 / 65.97
Volume 2.42M
Avg Volume 3.05M
Exchange NASDAQ
Shares Outstanding 52.71M
Market Cap 1.18B
EPS -7.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of CLVS February 15th Options Trading

First Week Of CLVS February 15th Options Trading

Investors in Clovis Oncology Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLVS options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Clovis Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Clovis Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

CHMP Grants Positive Opinion For New Indication Of Clovis Oncology's Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

CHMP Grants Positive Opinion For New Indication Of Clovis Oncology's Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an additional indication to include...

Clovis Oncology Announces Positive Outcome In European Opposition Proceeding Related To Rubraca®

Clovis Oncology Announces Positive Outcome In European Opposition Proceeding Related To Rubraca®

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153 in amended form covering certain crystalline forms of rucaparib camsylate,...

First Week Of CLVS July 2019 Options Trading

First Week Of CLVS July 2019 Options Trading

Investors in Clovis Oncology Inc saw new options become available this week, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Clovis Oncology Announces Second U.S. Patent Issued In Rucaparib High Dosage Strength Tablet Patent Family With Expiration In 2035

Clovis Oncology Announces Second U.S. Patent Issued In Rucaparib High Dosage Strength Tablet Patent Family With Expiration In 2035

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations.

Clovis Oncology To Present At The Credit Suisse 27th Annual Healthcare Conference

Clovis Oncology To Present At The Credit Suisse 27th Annual Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Announces Third Quarter 2018 Operating Results

Clovis Oncology Announces Third Quarter 2018 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the remainder of 2018.

Clovis Oncology Presents Initial Results From The Ongoing Rubraca® (rucaparib) TRITON Program In Metastatic Castration Resistant Prostate Cancer (mCRPC) At ESMO 2018 Congress

Clovis Oncology Presents Initial Results From The Ongoing Rubraca® (rucaparib) TRITON Program In Metastatic Castration Resistant Prostate Cancer (mCRPC) At ESMO 2018 Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced initial data from its ongoing Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress (European Society for Medical Oncology).

How Clovis Calls Prices Increased Overnight

How Clovis Calls Prices Increased Overnight

Trying to find a bottom in share price can be difficult, but these investors may have wanted to wager a retrace was do with an equivalent 2.18% 'stop-loss' should their idea take longer to play out.

Clovis Oncology To Announce Third Quarter 2018 Financial Results And Host Webcast Conference Call On October 30

Clovis Oncology To Announce Third Quarter 2018 Financial Results And Host Webcast Conference Call On October 30

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2018 financial results on Tuesday, October 30, 2018, after the close of the U.

Clovis Oncology Appoints Two New Directors To Its Board

Clovis Oncology Appoints Two New Directors To Its Board

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today the appointment of Robert W.

2 Stocks I'm Buying This Week as Investors Flee Small-Cap Biotechs

2 Stocks I'm Buying This Week as Investors Flee Small-Cap Biotechs

This is why I always have some 'dry powder' to deploy during these temporary hiccups.

Clovis Oncology To Highlight Results From Rubraca® (rucaparib) TRITON Prostate Program At ESMO 2018 Congress

Clovis Oncology To Highlight Results From Rubraca® (rucaparib) TRITON Prostate Program At ESMO 2018 Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four posters featuring data and highlighting studies from the Rubraca clinical development program will be presented at the ESMO 2018 Congress (European Society for Medical Oncology), 19-23...

Interesting CLVS Put And Call Options For January 2021

Interesting CLVS Put And Call Options For January 2021

Investors in Clovis Oncology Inc saw new options become available this week, for the January 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Clovis Oncology To Present At The Morgan Stanley Global Healthcare Conference

Clovis Oncology To Present At The Morgan Stanley Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

Relative Strength Alert For Clovis Oncology

Relative Strength Alert For Clovis Oncology

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Clovis Oncology Announces First Patient Enrolled In The Phase 3 ATHENA Trial

Clovis Oncology Announces First Patient Enrolled In The Phase 3 ATHENA Trial

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis' Rubraca ® (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers...

Clovis Oncology Announces Second Quarter 2018 Operating Results

Clovis Oncology Announces Second Quarter 2018 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the second half of 2018.

Buy These 3 Risky Biotech Stocks

Buy These 3 Risky Biotech Stocks

Is the pharma sector fever heating up in 2H18? Drug investors, get ready as there could be some good trades to be made.

Clovis Oncology To Announce Second Quarter 2018 Financial Results And Host Webcast Conference Call On August 1

Clovis Oncology To Announce Second Quarter 2018 Financial Results And Host Webcast Conference Call On August 1

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2018 financial results on Wednesday, August 1, 2018, after the close of the U.

Clovis Oncology Receives EMA Validation For Its Application For A New Indication For Rubraca®▼ (rucaparib) As Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology Receives EMA Validation For Its Application For A New Indication For Rubraca®▼ (rucaparib) As Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ® (rucaparib) to include maintenance treatment of adult patients...

Clovis Oncology To Present At The Goldman Sachs 39th Annual Global Healthcare Conference 2018

Clovis Oncology To Present At The Goldman Sachs 39th Annual Global Healthcare Conference 2018

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Submits Application To EMA To Expand Use Of Rubraca®▼ (rucaparib) To Include Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology Submits Application To EMA To Expand Use Of Rubraca®▼ (rucaparib) To Include Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the submission of a regulatory application to the European Medicines Agency (EMA), as part of a type II variation seeking to expand the marketing authorization for Rubraca (rucaparib) to include...

Groupon, Applied Materials, Adobe Systems: 'Mad Money' Lightning Round

Groupon, Applied Materials, Adobe Systems: 'Mad Money' Lightning Round

Jim Cramer weighs in on Groupon, Applied Materials, Adobe Systems, Cara Therapeutics, Watsco, CBRL Group, Pilgrim's Pride and more.

TheStreet Quant Rating: D- (Sell)